← Leaderboards
Jinshyun Ruth Wu-Wong
Vidasym, Inc.
$2,425,471
Attributed
$2,654,902
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2011–16$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$2,654,902 · 6
By mechanism
R44$1,480,983 · 1
R43$715,056 · 3
R41$458,863 · 2
Top collaborators
- Yan Chun Li2 shared
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsDoseCommercial ApplicationMarketingPenetrationCalciumPhase 2 StudyTechnological InnovationSafetySalesHealthcareAdverse EffectsToxicologyMetabolismExhibitsToxic EffectVitamin D3 ReceptorCalcitriolClinical TrialsScale UpPhase 1 StudyMedicalSerumDrug Prescriptions
Grant awards (6)
Novel drug VS-105 for treatment of osteoporosis$1,480,983
R44 · FY2016 · AR · contact PI
New drug VS-110 for treating inflammatory bowel diseases$299,216
R41 · FY2013 · DK · contact PI
Novel Drug VS-105 for Treatment of Osteoporosis$278,579
R43 · FY2013 · AR · contact PI
New drug VS-501 for treating hyperphosphatemia in chronic kidney disease$217,354
R43 · FY2012 · DK · contact PI
Novel drug VS-105 for treatment of diabetic nephropathy$159,647
R41 · FY2012 · DK · contact PI
New drug Vida-5 for treating chronic kidney disease progression$219,123
R43 · FY2011 · DK · contact PI